Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting ADAM10 in Cancer and Autoimmunity

Frontiers in Immunology(2020)10.3389/fimmu.2020.00499Source: DataRank Database

Targeting ADAM10 in Cancer and Autoimmunity is a research paper published in Frontiers in Immunology (2020). On theSindex it has a DataRank of 0. It has been cited 112 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access112 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: goldTopics (31)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Anuj Tharakan,Rebecca Martin ORCID,Timothy M. Smith ORCID

Live enrichment

PubMed:32265938

Foundation for the National Institutes of Health

Grant: R56AI139658

National Institutes of Health

Grant: 1R56AI139658-01A1

IL-25 as a master regulator of extrafollicular benign IgE

goldLicense: cc-by

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.00499/pdf

publisherhttps://www.frontiersin.org/article/10.3389/fimmu.2020.00499/full

repositoryhttps://doaj.org/article/19750701edf34e1eb8ff3720ae65f34d

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7105615

https://doi.org/10.3389/fimmu.2020.00499

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

hodgkin lymphomaImmunologyDrug Evaluation, PreclinicalAntineoplastic AgentsHydroxamic AcidsNKG2DAutoimmune DiseasesSubstrate SpecificityADAM10 Proteinbreast cancerNeoplasmsHumansMulticenter Studies as TopicProtease InhibitorsMolecular Targeted TherapymetalloproteasesClinical Trials as TopicReceptors, NotchglioblastomaMembrane ProteinsCell DifferentiationDipeptidesRC581-607ADAM10 inhibitorsNeoplasm ProteinsImmunologic diseases. AllergyAmyloid Precursor Protein SecretasesSignal Transduction

Sustainable Development Goals

SDG 3: 3. Good health